BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2013

View Archived Issues

High spatio-temporal resolution of broad-spectrum antibacterial activity using light

Read More

Nanomerics presents in vivo results for novel nanoparticle LENK formulation

Read More

TR-L-382 plus pregabalin shows promise in preclinical models of neuropathic pain

Read More

Novel cannabinoid CB2 receptor modulator tested in mice with TBI

Read More

Egalet enters abuse-deterrent hydrocodone collaboration with Shionogi

Read More

Interleukin Genetics to launch PerioPredict periodontal disease test

Read More

Genomic Health licenses Almac technology to develop test to determine chemotherapy benefit

Read More

DBV Technologies forms collaboration agreement for whooping cough booster vaccine

Read More

ImStar Therapeutics names drug candidate for amyotrophic lateral sclerosis

Read More

Novel malaria vaccine from the University of Oxford shows enhanced immunogenicity in vivo

Read More

Phase II acromegaly study of ATL-1103 cleared to continue by DSMB

Read More

Treatment begins in Bone Therapeutics' phase IIb/III study of PREOB in non-union fractures

Read More

FibroGen reports interim data from phase II FG-3019 study

Read More

FDA grants priority review to Dalvance NDA

Read More

GSK plans phase II study of GSK-2586184 for ulcerative colitis

Read More

Aurora kinase A inhibitor synergized with taxanes for the treatment of drug-resistant cancers

Read More

A team of researchers at Ariad Pharmaceuticals discloses novel EGFR inhibitors for cancer

Read More

Merck & Co. synthesizes new CGRP receptor antagonists for migraine

Read More

New O-GlcNAcase inhibitors discovered by Alectos Therapeutics and Merck & Co.

Read More

Novel ALK tyrosine kinase receptor inhibitors reported

Read More

New SGLT1 inhibitors for diabetes patented by Eli Lilly

Read More

Lycera and Merck & Co. divulge novel nuclear receptor ROR-gamma inhibitors

Read More

Eisai seeks Japanese approval of Pariet for new indication, new formulation

Read More

FDA approves Velphoro to treat hyperphosphatemia in patients with CKD on dialysis

Read More

FDA approves Varithena for the treatment of patients with incompetent veins

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing